Walleye Trading LLC Altimmune, Inc. Transaction History

Walleye Trading LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $378,292 - $635,550	-46,021 Reduced 74.71%	15,579 $158,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $89,024 - $483,391	41,600 Added 208.0%	61,600 $693,000
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $38,952 - $55,993	-16,230 Reduced 44.8%	20,000 $52,000
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $23,753 - $41,103	-6,885 Reduced 15.97%	36,230 $127,000
Q1 2023 May 15, 2023	SELL	$4.19 - $16.83 $147,525 - $592,567	-35,209 Reduced 44.95%	43,115 $181,000
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $684,551 - $1.29 Million	78,324 New	78,324 $1.29 Million
Q2 2022 Aug 08, 2022	BUY	$3.94 - $11.77 $141,599 - $423,002	35,939 New	35,939 $420,000
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $289,589 - $463,834	-49,083 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $426,531 - $612,555	49,083 New	49,083 $450,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.